Cantor Fitzgerald

Cantor Fitzgerald is a global financial services firm known primarily for its broker-dealer, capital markets, and investment banking businesses, with selective principal investing and venture capital activity across technology, healthcare, real estate, and financial services. As a venture investor, Cantor’s posture is opportunistic rather than thematic — they participate in growth-stage and pre-IPO rounds, often through dedicated funds or balance-sheet investments, and their healthcare exposure has typically been in clinical-stage biotech, diagnostics, and selective digital health where IPO or strategic exit pathways are clear. For healthcare AI founders, Cantor is most relevant at later stages — Series C and beyond — when you are preparing for an IPO or strategic transaction and want a financial-services counterparty that can advise on capital markets pathways and provide growth capital. Check sizes at this stage are plausibly $5M to $25M-plus depending on the structure. Stage focus skews late, not early. Founders who should approach: revenue-stage healthcare AI companies preparing for growth rounds with a credible IPO or strategic-sale narrative, particularly those who would benefit from a banker-investor relationship. Founders who should not approach: seed and Series A teams, pre-revenue science plays, and any company without a clear capital-markets or M&A pathway. Be aware that taking Cantor onto the cap table can shape banker selection later — manage that strategic dynamic carefully. Entry path is through the Cantor investment banking and capital markets teams, growth-stage VCs that co-invest with Cantor, and CFOs who have worked with Cantor as a banker before. Cold outbound is unlikely to convert at this scale.